155 related articles for article (PubMed ID: 17936216)
1. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari M; Catania A; Magnani G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
[No Abstract] [Full Text] [Related]
2. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
3. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia.
Basse G; Ribes D; Kamar N; Esposito L; Rostaing L
Clin Nephrol; 2006 Nov; 66(5):395-6. PubMed ID: 17140171
[No Abstract] [Full Text] [Related]
4. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.
Cohen C; Mekinian A; Saidenberg-Kermanac'h N; Stirnemann J; Fenaux P; Gherardi R; Fain O
Ann Rheum Dis; 2012 Apr; 71(4):628-9. PubMed ID: 22121135
[No Abstract] [Full Text] [Related]
5. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
[TBL] [Abstract][Full Text] [Related]
6. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
Cai FZ; Ahern M; Smith M
J Rheumatol; 2006 Jun; 33(6):1197-8. PubMed ID: 16755669
[TBL] [Abstract][Full Text] [Related]
9. [Kidney involvement in mixed cryoglobulinemia: which treatment?].
Cacoub P
Presse Med; 2012 Mar; 41(3 Pt 1):254-9. PubMed ID: 22192935
[TBL] [Abstract][Full Text] [Related]
10. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
[TBL] [Abstract][Full Text] [Related]
11. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
[TBL] [Abstract][Full Text] [Related]
12. Cryoglobulin-induced cardiomyopathy.
Karras A; Potier L; Reboux AH; Coldea N; Perdrix L; Jacquot C; Mousseaux E
J Am Coll Cardiol; 2010 Feb; 55(7):e13. PubMed ID: 20170783
[No Abstract] [Full Text] [Related]
13. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II.
Moberg P; Charles JF; Respicio G; Venna SS; Rooney T
Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729
[TBL] [Abstract][Full Text] [Related]
14. Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
Emmanuel B; Sidique N; Zhang X; Poonia B; Sneller MC; Kottilil S
J Viral Hepat; 2017 Feb; 24(2):128-131. PubMed ID: 27666584
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
St Clair EW
Arthritis Rheum; 2012 Mar; 64(3):604-8. PubMed ID: 22147537
[No Abstract] [Full Text] [Related]
17. Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab.
Baerlecken NT; Schmidt RE
Clin Rheumatol; 2013 Mar; 32 Suppl 1():S19-20. PubMed ID: 20213127
[TBL] [Abstract][Full Text] [Related]
18. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Cacoub P; Terrier B; Saadoun D
Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
[No Abstract] [Full Text] [Related]
19. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
Guillevin L
Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
[No Abstract] [Full Text] [Related]
20. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
